A federal judge in Boston tossed a class action securities lawsuit filed against Boston Scientific Corp. (NYSE:BSX) accusing the company of misleading investors about problems with its Taxus Express drug-eluting stent.
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
OrbusNeich Medical Inc. wasted no time after winning a new patent from the U.S. Patent & Trademark Office, filing a motion to amend a patent infringement lawsuit against Boston Scientific Corp. (NYSE:BSX) to include its new intellectual property.
The USPTO granted the Hong Kong-based firm, which has its U.S. headquarters in Ft. Lauderdale, Fla., a patent covering a "Stent with Helical Elements," according to a press release. The patent, granted March 23, covers an expandable stent with "a plurality of helical segments," according to the release.
Boston Scientific Corp. (NYSE:BSX) is looking to run a double-reverse with its appeal of a judge’s decision in its long-running war with Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. over stent patents.
The Natick, Mass.-based medical device maker filed an appeal with the U.S. Court of Appeals for the Federal Circuit seeking to reverse an August 2009 ruling, which itself reversed a prior decision, regarding the enforceability of a pair of Cordis Corp. patents.
NMT Medical Inc. (NSDQ:NMTI) isn’t letting a little snow get in its way. Having salvaged an offering of stock, debt and warrants delayed by a February blizzard with a $6 million private placement, the company filed another registration for a similar, $30 million public offering with the Securities and Exchange Commission.
Cordis Corp. tapped the lead investigator in clinical trials of its Cypher drug-eluting stent, Dr. Christian Spaulding, to be its worldwide vice president of medical affairs.
The Johnson & Johnson (NYSE:JNJ) subsidiary said Spaulding will lead its global clinical strategy starting June 1 from his home base in Paris.
ATS Medical Inc. (NSDQ:ATSI) won a nod north of the border for its Simulus rings to repair defective heart valves.
The Minneapolis-based medical device maker said Health Canada, the Canadian equivalent of the Food & Drug Administration, cleared its mitral and tricuspid valve repair rings for sale in that country.
Medtronic Inc. (NYSE:MDT) launched what’s expected to be a 1,000-patient study of a catheter-based system it hopes will become a less-invasive — and highly lucrative — alternative to open-heart surgery for valve replacement.
Medtronic’s CoreValve system allows a replacement heart valve to be placed in a patient’s body via a catheter inserted in the femoral artery, near the groin. A catheter is a thin, flexible tube that can be inserted into a body cavity to open a passageway or to allow fluids to pass through.
It’s shaping up to be a tough day for Medtronic Inc. (NYSE:MDT), as news of a federal false claims investigation follows questions from the Food & Drug Administration about a study of one of its deep-brain stimulation devices.
The Fridley, Minn.-based medical devices monolith revealed in a March 10 securities filing that the U.S. Attorney for Massachusetts issued a "civil investigative demand" Feb. 22 for documents in a false claims probe into the relationship of its CoreValve subsidiary with the Burlington, Mass.-based Lahey Clinic, "specifically relating to cardiologists at the clinic, CoreValve Inc. … and the Lahey Clinic, and certain employees of both [Medtronic] and the clinic, among other topics."
Boston Scientific Corp. (NYSE:BSX) may have won the most recent round in its stent patents war with Johnson & Johnson (NYSE:JNJ), but that didn’t stop the Natick, Mass.-based devices giant from cross-appealing a Delaware judge’s ruling.
The patents in question are at the heart of complicated legal wrangling involving Boston Scientific, its New Brunswick, N.J.-based rival and competitor/partner Abbott (NYSE:ABT). The dispute centers around Boston Scientific’s Promus stent, a private-label version of Abbott’s Xience V stent, and the JNJ subsidiary Cordis Corp.’s Cypher.
LeMaitre Vascular Inc. (NSDQ:LMAT) ended 2009 swinging from red to black, riding strong sales in its vascular division to positive top- and bottom-line growth for the year.
The Burlington, Mass.-based peripheral vascular device maker posted sales of $13.6 million during the three months ended Dec. 31, 2009, up 13 percent compared with the $12 million in sales the company reported during the same period in 2008.
The increased sales helped the company boost its bottom line to $1.3 million, compared to a $312,000 profit for Q4 2008.